Kadmon D - Search Results

1

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM. Canto EI, et al. Among authors: kadmon d. Urology. 2004 May;63(5):905-10; discussion 910-1. doi: 10.1016/j.urology.2003.12.037. Urology. 2004. PMID: 15134977

2

Elevated plasma chromogranin-A concentrations in prostatic carcinoma.

Kadmon D, Thompson TC, Lynch GR, Scardino PT. Kadmon D, et al. J Urol. 1991 Aug;146(2):358-61. doi: 10.1016/s0022-5347(17)37793-5. J Urol. 1991. PMID: 1856931

3

The role of transrectal ultrasonography in the diagnosis and management of prostatic and seminal vesicle cysts.

Shabsigh R, Lerner S, Fishman IJ, Kadmon D. Shabsigh R, et al. Among authors: kadmon d. J Urol. 1989 May;141(5):1206-9. doi: 10.1016/s0022-5347(17)41216-x. J Urol. 1989. PMID: 2651723

4

Treatment with finasteride following radical prostatectomy for prostate cancer.

Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, et al. Andriole G, et al. Among authors: kadmon d. Urology. 1995 Mar;45(3):491-7. doi: 10.1016/s0090-4295(99)80021-1. Urology. 1995. PMID: 7533461 Clinical Trial.

5

Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth.

Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Timme TL, et al. Among authors: kadmon d. Microsc Res Tech. 1995 Mar 1;30(4):333-41. doi: 10.1002/jemt.1070300408. Microsc Res Tech. 1995. PMID: 7541677 Review.

6

Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.

Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Slawin K, et al. Among authors: kadmon d. Cancer Res. 1993 Oct 1;53(19):4461-5. Cancer Res. 1993. PMID: 8402613

7

Pitfalls in interpreting prostate specific antigen velocity.

Kadmon D, Weinberg AD, Williams RH, Pavlik VN, Cooper P, Migliore PJ. Kadmon D, et al. J Urol. 1996 May;155(5):1655-7. J Urol. 1996. PMID: 8627846 Clinical Trial.

8

Intracranial metastases as the first manifestation of prostate cancer.

Sutton MA, Watkins HL, Green LK, Kadmon D. Sutton MA, et al. Among authors: kadmon d. Urology. 1996 Nov;48(5):789-93. doi: 10.1016/S0090-4295(96)00238-5. Urology. 1996. PMID: 8911530 Review.

9

Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities.

Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Timme TL, et al. Among authors: kadmon d. World J Urol. 1995;13(6):324-8. doi: 10.1007/BF00191212. World J Urol. 1995. PMID: 9116750

10

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J. Andriole GL, et al. Among authors: kadmon d. Urology. 1998 Aug;52(2):195-201; discussion 201-2. doi: 10.1016/s0090-4295(98)00184-8. Urology. 1998. PMID: 9697781 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters